DOCSLIB.ORG

Medical Research Council Annual Report and Accounts 2006/07 HC 93

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Medical Research Council Annual Report and Accounts 2006/07 HC 93 06/07 Annual Report and Accounts © Crown Copyright 2006 The text in this document (excluding any Royal Arms and departmental logos) may be reproduced free of charge in any format or medium providing that it is reproduced accurately and not used in a misleading context. The material must be acknowledged as Crown copyright and the title of the document specified. Any queries relating to the copyright in this document should be addressed to The Licensing Division, HMSO, St Clements House, 2-16 Colegate, Norwich, NR3 1BQ. Fax: 01603 723000 or e-mail: licensing@cabinet-office.x.gsi.gov.uk 2 MRC Annual Report and Accounts 2006/07 Medical Research Council Annual Report and Accounts 2006/07 Presented to Parliament by the Secretary of State, and by the Comptroller and Auditor General in pursuance of Schedule I, Sections 2(2) and 3(3) of the Science and Technology Act 1965. Sir John Chisholm Chairman Professor Sir Leszek Borysiewicz Deputy Chairman and Chief Executive Ordered by and printed on London: The Stationery Office 6 February 2008 Price: £18.55 HC 93 The Medical Research Council The MRC RCUK The Medical Research Council (MRC) was set up in 1913 to administer Research Councils UK (RCUK) is a partnership of the seven (formerly public funds for medical research. It was incorporated under its eight) UK Research Councils – public bodies funded mainly by the UK present title by Royal Charter in 1920. A supplemental charter was Government via OSI. granted in 1993 describing the MRC’s new mission following the 1993 government white paper on science and technology. The MRC’s Led by the research council chief executives, RCUK has an overall Royal Charter and Mission were amended in July 2003. The MRC aim for the UK research councils to be recognised as the benchmark receives an annual grant-in-aid from Parliament through the Office around the world in terms of the impact they have and the ways they of Science and Innovation (OSI), part of the Department of Trade work. Its mission is to optimise the ways that research councils work and Industry (DTI)1. The MRC also receives funds from other sources together to deliver their goals, to enhance the overall performance including government departments, international agencies, industry and impact of UK research, training and knowledge transfer and to be and medical research charities. recognised by academia, business and Government for excellence in research sponsorship. The MRC’s strategic aims are developed in consultation with stakeholders and with reference to the mission enshrined in the MRC Charter and to the objectives set out in the 2004 Government Spending Review, which agreed allocations for 2006/07 and 2007/08. Its aims also contribute to the OSI Public Service Agreement target of improving the international performance of the UK’s science and engineering base, exploitation of the UK science base, and the innovation performance of the UK economy. The MRC’s mission is to: >g\hnkZ`^Zg]lniihkmab`a&jnZebmrk^l^Zk\apbmama^ aim of improving human health. Ikh]n\^ldbee^]k^l^Zk\a^klZg]mhZ]oZg\^Zg] disseminate knowledge and technology to improve the jnZebmrh_eb_^Zg]^\hghfb\\hfi^mbmbo^g^llbgma^ND' Ikhfhm^]bZeh`n^pbmama^in[eb\Z[hnmf^]b\Zek^l^Zk\a' The Annual Report describes the MRC’s progress between 1 April 2006 and 31 March 2007 in meeting our strategic aims set out in the MRC Strategic Plan 2004-2007 and the objectives set out in the Government Science Budget allocations for the period. A selection of outstanding achievements by MRC scientists during the period highlighted in the MRC Annual Review 2006/07. For more information about MRC activities and to view MRC publications visit www.mrc.ac.uk. 1 The Department for Innovation Universities and Skills (DIUS) was established in June 2007 following the dissolution of the Department of Trade and Industry. The new Department brings together the science and innovation responsibilities from the DTI, and skills, further and higher education from the Department for Education and Skills. 2 MRC Annual Report and Accounts 2006/07 MRC Council Members 2006/07 The MRC is governed by its Council, which directs and oversees corporate policy and scientific strategy, ensures that the MRC is effectively managed, and makes major policy and spending decisions. Council members share collective responsibility for the MRC’s actions and performance. Responsibility for implementing the Council’s strategy and decisions is delegated to the Chief Executive, Professor Colin Blakemore. Sir John Chisholm Dr Lefkos Middleton Chairman Independent consultant (appointed 1 October 2006) (formerly GlaxoSmithKline to December 2006) Professor Colin Blakemore Mr John Neilson Deputy Chairman and Chief Executive OSI observer Professor David Armstrong Professor Genevra Richardson King’s College London King’s College London Mr Michael Brooks Professor John Savill Financial Management Consultant University of Edinburgh Dr Harry Burns Professor Herb Sewell Scottish Executive Health Department University of Nottingham Professor Kay Davies Professor Michael Wakelam University of Oxford The Babraham Institute (formerly University of Birmingham to 31 Jan 2007) Professor Sally Davies (appointment ended 31 March 2007) Department of Health Professor Carol Dezateux Outgoing members University College London Sir Anthony Cleaver Dr Peter Fellner Chairman Vernalis, Plc (appointment ended 30 September 2006) Professor Christopher Kennard Mr Derek Flint Imperial College London Non-Executive Director of Alliance and Leicester Insurance plc (appointed 1 August 2006) (appointment ended 31 July 2006) Dr Michael McBride Professor Alan North Northern Ireland Department of Health, University of Manchester Social Services and Public Safety (appointment ended 31 July 2006) (appointed 1 November 2006) Professor Andrew McMichael University of Oxford MRC Annual Report and Accounts 2006/07 3 Contents Foreword from the Chairman and Chief Executive page 6 Executive summary page 8 Delivering discovery science for health page 11 Research priorities, strategy and partnerships page 11 Supporting research excellence page 20 People page 25 Human resources page 25 Research training page 26 Bringing discoveries to the market page 31 Translating research into healthcare page 31 Fast tracking drug discovery page 32 Engaging with people page 35 Public engagement page 35 Consultation page 35 Public involvement page 36 Partnerships in communication page 36 Working with parliamentarians page 36 Explaining the link between research and the health of the public page 37 Good research practice and efficiency page 39 Good research practice and ethics page 39 Effective business practice page 41 Management Commentary page 45 Remuneration Report 2006/07 page 50 Annual Accounts 2006/07 page 55 MRC Annual Report and Accounts 2006/07 5 Foreword from the Chairman and Chief Executive It is with great pleasure that I have taken on the role of Chairman As I approach the end of my term as Chief Executive, I reflect on of the MRC, during this interesting transition. I arrived just as the the MRC’s achievements with pride. Over our long history, we have Cooksey review was coming to a close and the MRC was beginning funded outstanding science. Many of the discoveries funded by to plan its future in a world where nations are competing on a basis the MRC have been translated – by us, the NHS, industry or other of how quickly they can innovate. There is no area of scientific funders – into outcomes to improve healthcare, public policies and endeavour more likely to change the course of human civilisation the economy. for the better over the next 20 years than medical research. Through the new structures, including partnership with the Office for Strategic The UK medical research system is today facing one of the biggest Coordination of Health Research (OSCHR) and the overarching strategy transformations since the foundation of the MRC 94 years ago. As boards, the MRC will strive, as it always has done, to fund excellent the MRC moves on to play a key role in the new integrated health discovery science to deliver optimal improvements to human health. strategy and to capitalise on the opportunities such change offers, I wish my successor, the MRC and all our scientists the very best for a As Chief Executive, Colin has been a determined advocate for the productive and prosperous future. MRC, and for the strength of UK science. He has raised the public and professional profile of the MRC nationally and internationally, and has effectively engaged the community in responding to Professor Colin Blakemore changing research and financial environments. On behalf of the Deputy Chairman and Chief Executive MRC’s Council, I would like to thank him for his contribution to the success of the MRC and wish him well for the future. Sir Lesek Borysiewicz, who replaces Colin as Chief Executive1, will now lead the MRC in the new environment of coordinated health research in the UK. His stature as a scientist and clinician reflects the importance of the role the MRC will play in a coordinated strategy for turning research findings into healthcare. Sir John Chisholm Chairman 1 Sir Leszek Borysiewicz was appointed 1 October 2007. 6 MRC Annual Report and Accounts 2006/07 Foreword continued… The Medical Research Council (MRC) has a proven track record for decisions taken on issues of structure and function later in the year, funding excellent discovery research in basic, clinical and population following the appointment of the MRC’s new Chief Executive, who science, and outstanding
Load more

Recommended publications
  • Pooled CRISPR-Activation Screening Coupled with Single-Cell RNA-Seq in Mouse Embryonic Stem Cells
    ll OPEN ACCESS Protocol Pooled CRISPR-activation screening coupled with single-cell RNA-seq in mouse embryonic stem cells Celia Alda-Catalinas, Melanie A. Eckersley-Maslin, Wolf Reik celia.x.aldacatalinas@gsk. com (C.A.-C.) wolf.reik@babraham.ac. uk (W.R.) Highlights Protocol for CRISPRa screens with single- cell readout to interrogate gene function Detailed description of CRISPRa screening procedures in mouse embryonic stem cells Detailed steps on how to construct derived single-cell sgRNA amplicon libraries CRISPR/Cas9 screens are a powerful approach to identify key regulators of biological processes. By combining pooled CRISPR/Cas9 screening with a single-cell RNA-sequencing readout, individual perturbations can be assessed in parallel both comprehensively and at scale. Importantly, this allows gene function and regulation to be interrogated at a cellular level in an unbiased manner. Here, we present a protocol to perform pooled CRISPR-activation screens in mouse embryonic stem cells using 103 Genomics scRNA-seq as a readout. Alda-Catalinas et al., STAR Protocols 2, 100426 June 18, 2021 ª 2021 The Authors. https://doi.org/10.1016/ j.xpro.2021.100426 ll OPEN ACCESS Protocol Pooled CRISPR-activation screening coupled with single-cell RNA-seq in mouse embryonic stem cells Celia Alda-Catalinas,1,4,7,* Melanie A. Eckersley-Maslin,1,5,6 and Wolf Reik1,2,3,8,* 1Epigenetics Programme, Babraham Institute, Cambridge CB22 3AT, UK 2Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK 3Centre for Trophoblast Research, University of
    [Show full text]
  • The Oxford – Cambridge Arc Home of the New Innovation Economy
    Economic Vision: The Oxford – Cambridge Arc Home of the New Innovation Economy April 2019 Contents 1 Introduction 3 2 The Economic Vision 8 3 The New Innovation Economy: Sectors 11 4 The Innovation & Growth Network 24 5 Achieving Ambitions 29 6 Conclusion: Critical Mass 35 | Introduction 1 Introduction 1.1 This vision’s purpose The purpose of the Economic Vision is to explain the Oxford - Cambridge Arc’s unified proposition as a globally leading innovation and growth catalyst. The Arc offers access to each of the critical ingredients for business and innovation-led growth. This collective offer represents a powerful and coherent expression of the region’s current assets and future potential. This Economic Vision for the Arc sets out an ambition and series of proposals designed to unlock the economic potential of the region and deliver transformative growth for the UK between now and 2050. It provides a vision for how the Arc can better connect its unique and world-leading assets to become truly globally competitive in frontier markets, both for business investment and for top talent. With a bolder brand and stronger international presence the Arc can continue to lead the whole of the UK to the forefront of global innovation excellence in the coming years and decades. 3 | Introduction This Economic Vision is built upon the foundation of This Economic Vision has been developed in the four local industrial strategies which currently partnership with the three LEPs and the Combined demarcate the Arc’s geographic area. These have Authority, who have been given a mandate by Central been prepared by the Oxfordshire (OxLEP), South Government to drive forwards the Economic Vision for East Midlands (SEMLEP) and Buckinghamshire the Arc: Thames Valley (BTVLEP) Local Enterprise Partnerships, as well as the Cambridgeshire & Peterborough Mayoral Combined Authority (CPCA).
    [Show full text]
  • The Use of Non-Human Primates in Research in Primates Non-Human of Use The
    The use of non-human primates in research The use of non-human primates in research A working group report chaired by Sir David Weatherall FRS FMedSci Report sponsored by: Academy of Medical Sciences Medical Research Council The Royal Society Wellcome Trust 10 Carlton House Terrace 20 Park Crescent 6-9 Carlton House Terrace 215 Euston Road London, SW1Y 5AH London, W1B 1AL London, SW1Y 5AG London, NW1 2BE December 2006 December Tel: +44(0)20 7969 5288 Tel: +44(0)20 7636 5422 Tel: +44(0)20 7451 2590 Tel: +44(0)20 7611 8888 Fax: +44(0)20 7969 5298 Fax: +44(0)20 7436 6179 Fax: +44(0)20 7451 2692 Fax: +44(0)20 7611 8545 Email: E-mail: E-mail: E-mail: apollo@acmedsci.ac.uk corportate@headoffice.mrc.ac.uk science.policy@royalsoc.ac.uk contact@wellcome.ac.uk Web: www.acmedsci.ac.uk Web: www.mrc.ac.uk Web: www.royalsoc.ac.uk Web: www.wellcome.ac.uk December 2006 The use of non-human primates in research A working group report chaired by Sir David Weatheall FRS FMedSci December 2006 Sponsors’ statement The use of non-human primates continues to be one the most contentious areas of biological and medical research. The publication of this independent report into the scientific basis for the past, current and future role of non-human primates in research is both a necessary and timely contribution to the debate. We emphasise that members of the working group have worked independently of the four sponsoring organisations. Our organisations did not provide input into the report’s content, conclusions or recommendations.
    [Show full text]
  • In Pursuit of an HIV Vaccine: an Interview with Andrew Mcmichael Andrew J Mcmichael
    McMichael BMC Biology 2013, 11:60 http://www.biomedcentral.com/1741-7007/11/60 INTERVIEW Open Access In pursuit of an HIV vaccine: an interview with Andrew McMichael Andrew J McMichael Andrew McMichael qualified in Medicine before doing a PhD in Immunology with Ita Askonas and Alan Williamson in the 1970s. His research during this time and later work done in his group has made a major contri- bution to our understanding of T-cell-mediated immunity against viral infections. Initially he worked on the immune response to influenza, but latterly studying the T cell re- sponse against HIV has been a major focus, and his group has designed and tested two candidate HIV vaccines in phase I clinical trials. Based through most of his research career in Oxford, he was knighted in 2008 for services to medical sciences, and has just completed 12 years as Director of the Weatherall Institute of Molecular Medicine. In this 30th year since the discovery of HIV as the cause of AIDS, we asked Sir Andrew to give us his per- sonal perspective on the progress towards a vaccine. Andrew J McMichael Would you like to start by telling us how and when you first started working on HIV? working on immune responses to HIV. A lot of virolo- We started in 1986 or 1987 when my laboratory was fo- gists were already working on it of course. So we cused on studying immune responses to influenza. I actu- thought we’d start on it in quite a small way, but realiz- ally had a clinical training fellow - Douglas Nixon - who ing that if the experiments worked, it would probably was studying to be a clinical virologist.
    [Show full text]
  • From the Chief Medical Officer Dr Michael Mcbride by EMAIL To: All
    From the Chief Medical Officer Dr Michael McBride BY EMAIL Castle Buildings Stormont Estate To: All NI Departments through the Civil BELFAST Contingencies Group, for onward distribution to BT4 3SQ all public authorities Tel: 028 9052 0563 Email: Michael.McBride@health-ni.gov.uk Your Ref: Our Ref: Date: 26 February 2020 Dear Colleagues CORONAVIRUS: (A) KEY PUBLIC HEALTH ADVICE (B) ACTION TO BE TAKEN BY PUBLIC AUTHORITIES 1 This letter updates the advice given in my letter of 6 February to all NI Departments and their public authorities, to reflect the recent changes in the case definition including reference to northern Italy. This letter supersedes the letter of 6 February. The purpose is to enable all NI Executive Departments and public authorities to prepare to respond to any and all potential eventualities arising from the current novel coronavirus (COVID-19) outbreak. It is essential that all Departments are assured that proportionate, appropriate and efficient arrangements are in place that are consistent with the key public health messages about novel coronavirus. 2 Each NI Department is asked to ensure that the letter is distributed to each public authority that they sponsor, including schools. Coronavirus: key facts 3 Coronaviruses are a large family of viruses, some of which cause illness in people, ranging from the common cold to more severe diseases such as MERS and SARS. As a group, coronaviruses are common across the world. The 2019 novel Coronavirus strain, now officially designated COVID-19 by the World Health Organisation, is a strain not previously seen in humans. On 31 December 2019 Chinese authorities notified the WHO of an outbreak of viral pneumonia in Wuhan City.
    [Show full text]
  • From the Chief Medical Officer Dr Michael Mcbride HSS(MD)93/2020
    From the Chief Medical Officer Dr Michael McBride HSS(MD)93/2020 Castle Buildings Stormont Estate FOR ACTION BELFAST Chief Executives, Public Health Agency/Health and Social BT4 3SQ Care Board/HSC Trusts/ NIAS Tel: 028 9052 0563 GP Medical Advisers, Health & Social Care Board Email: Michael.McBride@health-ni.gov.uk All General Practitioners and GP Locums (for onward distribution to practice staff) OOHs Medical Managers (for onward distribution to staff) Our Ref: HSS(MD)93/2020 RQIA Date: 30 December 2020 PLEASE SEE ATTACHED FULL CIRCULATION LIST Dear Colleague DEPLOYMENT OF THE ASTRAZENECA COVID-19 VACCINE IN NORTHERN IRELAND AND UPDATED JCVI ADVICE ON COVID-19 VACCINES ACTION REQUIRED Chief Executives must ensure this information is drawn to the attention of all staff involved in the COVID-19 vaccination programme. The PHA must ensure this information is cascaded to their staff working on COVID-19 vaccine deployment and the health protection team. The HSCB must ensure this information is cascaded to all General Practitioners and practice managers for onward distribution to all staff involved in the COVID-19 vaccination programme. INTRODUCTION 1. You will be aware that on 30 December the COVID-19 vaccine developed by AstraZeneca/Oxford, was granted approval for use following a thorough review carried out by the Medicines and Healthcare products Regulatory Agency (MHRA). In addition to this announcement the Joint Committee on Vaccination and Immunisation (JCVI) have also issued further updated advice in relation to the COVID-19 vaccination programme. 2. This letter sets out a broad overview of how the AstraZeneca vaccine will be deployed and highlights some of the updated advice from JCVI, particularly in relation to the intervals between doses of the Pfizer/BioNTech or AstraZeneca vaccines.
    [Show full text]
  • Open Letter to the ICO, Cmos and UK Data Providers: Reducing Barriers to Data Access for Research in the Public Interest – Lessons from COVID-19
    Open letter to the ICO, CMOs and UK data providers: Reducing barriers to data access for research in the public interest – lessons from COVID-19 Dear Ms Elizabeth Denham CBE, Prof Sir Chris Whitty, Dr Frank Atherton, Dr Gregor Smith, Dr Michael McBride, Ms Sarah Wilkinson, Rt Hon. Gavin Williamson MP, Sir Ian Diamond, Prof David Ford, Prof Kerina Jones, Prof Ronan Lyons, Ms Siobhan Carey CBE, Mr Roger Halliday, Mr Frank Hester OBE, Dr Janet Valentine, and Mr Duncan Selbie, Letter sent by email on 6th July 2020 The COVID-19 outbreak has sparked increased awareness of the importance of timely, system-wide data for examining trends and modelling different scenarios to inform policy response.1-5 The scale and speed of data access and use has been unprecedented in public health history. Pre-print articles sharing results before peer review have proliferated (with implications for research quality6 7) and over 500 vaccine and treatment clinical trials have been initiated in record time.8 The entire economy of knowledge production related to COVID-19 has been accelerated, with the understanding that, if we wait for perfect information before acting, we will be too late. COVID-19 is providing valuable lessons on improving data access and the importance of using data for efficient and effective service response. This situation contrasts sharply with the cumbersome processes usually faced by researchers using administrative (or routinely-collected) health data to inform policy-making on other topics, resulting from systems that are not purpose-built for research and summarised by four key obstacles. First, the cost of using administrative data is prohibitive.
    [Show full text]
  • Minutes of the Proceedings
    MINUTES OF THE PROCEEDINGS at the Thirty‐sixth Meeting of the COUNCIL of the IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE The Thirty‐sixth Meeting of the Council was held in the Council Room, 170 Queen’s Gate, South Kensington Campus, Imperial College London, at 10:00 a.m. on Friday, 16th May 2014, when there were present: The Baroness Manningham‐Buller (Chair), Professor A. Anandalingam, Mr. C. Brinsmead, Dame Ruth Carnall, Mrs. P. Couttie, Professor M.J. Dallman, Mr. P. Dilley, Mr. D. Goldsmith, Professor N. Gooderham, Professor Dame Julia Higgins, Professor D.P.A. Kelleher, Ms. J.R. Lomax, Professor J. Magee, Mr. J. Newsum, Mr. S. Newton, Ms. K. Owen, Mr. M. Sanderson, Professor J Stirling, the President & Rector and the Clerk to the Court and Council. Apologies Mr. I. Conn. MINUTES Council – 7th February 2014 1. The Minutes of the thirty‐fifth Meeting of the Council, held on Friday, 7th February 2014, were taken as read, confirmed and signed. CHAIR’S REPORT 2. The Chair advised members that, following his appointment as Chair of the Chelsea and Westminster Hospital NHS Foundation Trust, Sir Thomas Hughes‐Hallett had resigned as a co‐opted member of the Council on 11 February. PRESIDENT & RECTOR’S REPORT 3. The President & Rector reported that this year’s Imperial Festival, held on 9th and 10th May, had received many visitors at the South Kensington campus to enjoy the various demonstrations, talks 1 Council 16th May 2014 and other activities on offer. What had started as a relatively modest pilot project in 2012 to explore how Imperial College London might share its research with more people had now evolved into a large‐scale and prominent annual fixture in the College’s calendar.
    [Show full text]
  • Supporting Doctors Throughout the COVID-19 Pandemic
    12 January 2021 Supporting doctors throughout the COVID-19 pandemic Dear Colleagues This year has started in a way we could all have barely imagined 12 months ago, and we wanted to write to thank all of you for your immense efforts. After the long ordeal of last year, we enter the New Year with the real hope that vaccination offers to control COVID and the very substantial impact that it has had on health, lives and livelihoods but with a significant surge in cases to deal with before that begins to take effect. There are many weeks ahead that are likely to be among the most challenging of all our professional lives. Doctors will be faced with many professional dilemmas and some may be pushed to the limits of physical and mental endurance. Please look after your colleagues - protracted, relentless crises are often much more draining than short intense ones. We wrote to you during the first wave of COVID-19 last Spring and again in the Autumn when infections once again began to rise. Those letters contained important advice concerning the application of clinical decisions in extreme circumstances and we would encourage you to read them if you have not already done so. We also append them for your information. Our view remains that clinical decision making must remain anchored in the principles of Good Medical Practice. This means it must also rightly take into account the realities of the situation in which we find ourselves. We would emphasise once again that a rational approach to varying practice in an emergency is part of a doctor’s professional response, and we would expect you to be professionally supported to do this.
    [Show full text]
  • Michael John Owen Wakelam 1955–2020
    obituary Michael John Owen Wakelam 1955–2020 We have lost a distinguished biochemist who dedicated his career to the study of phosphatidylinositol signalling in metabolic regulation and to the advancement of lipidomics. ichael John Owen Wakelam passed away on 31 March, 2020 at the Mage of 64, much too early. He became known to colleagues and friends as a scientist highly regarded for his research. He was honoured in 2018 with the Morton Lectureship of the Biochemical Society and was elected a fellow of the Royal Society of Biology. In 2019, he was elected a member of the Academia Europaea. Academic career It was not by chance that Michael turned his focus to phosphatidylinositols (PIs) and lipid signalling. He was a student and later a professor at the University of Birmingham at a time when Britain was the world’s hub of pioneering phospholipid research, such as that by J. N. Hawthorne and Bob Michell on PI in Birmingham. Bob Michell inspired Michael extraordinarily, and they even published a joint review. Subsequently, Michael moved to Cambridge to serve as the director of the Babraham Institute, where Credit: Babraham Institute Rex Dawson and Robin Irvine studied phospholipids, particularly PI metabolism and signalling. A joint publication by Michael and Irvine appeared as well. the Babraham Institute, and he received an the Keystone Symposia on Molecular and Certainly, Michael’s scientific engagement honorary professorship in lipid signalling at Cellular Biology. can be seen in the tradition of these eminent the University of Cambridge Clinical School. phospholipid scientists. In addition, he was an honorary professor Lipid signalling and metabolism Michael’s career path is impressive.
    [Show full text]
  • 24, 2021 Program Book Table of Contents
    June 21 – 24, 2021 Program Book Table of Contents Genetics Society of America . 3 Conference Organizers . 5 International C. elegans Board 2021 . 7 Sponsors . 9 Schedule of Events . 11 General Information . 16 Conference App . .. 17 Oral Presenters . 17 Poster Presenters . 17 Viewing Oral Sessions . 18 Attending Live Poster Sessions . .. 18 Live Poster Session Schedule . 19 Sponsor and Exhibitor Education Sessions . 21 Daily Meet-ups via Zoom and Remo . 22 Viewing Virtual Posters on the App . 23 Slack Chat Channels . 23 Job Postings . 23 Presenting Author Index . 23 Conference Policies . 24 Exhibits . 27 Oral Presentation and Workshop Session Listings . 29 Poster Session Listings . 58 23rd International C. elegans Conference | 2 Genetics Society of America Genetics Society of America GSA is an international scientific society representing more than 5,000 researchers and educators around the world. As well as connecting researchers through conferences and career programs, we publish two peer- edited scholarly journals, GENETICS and G3: Genes|Genomes|Genetics. We encourage you to join GSA so you can make use of exclusive member benefits and get involved in the Society’s many programs, including professional development training, awards, advocacy, and more. Join us as we work to advance the field and serve our community. Visit genetics-gsa.org for more information. GENETICS has been innovating since 1916, publishing high quality original research across the breadth of the field. G3: Genes|Genomes|Genetics is an open access journal that publishes high quality, useful results regardless of perceived impact. 2021 GSA Board of Directors Officers Directors Journal Editors Hugo Bellen, President Swathi Arur Brenda J.
    [Show full text]
  • SGM Meeting Abstracts: UMIST, 8-11 September 2003
    CONTENTS Page MAIN SYMPOSIUM Exploiting Genomes: Bases to Megabases in 50 Years 3 Offered papers (Poster) 6 GROUP SYMPOSIUM Cells & Cell Surfaces Group: Symposium: Microbial sensing and signalling 13 Offered papers (Poster) 14 Education & Training Group / Systematics & Evolution Group: Symposium: Making sense of bioinformatics: seeing the wood for the trees 19 Offered papers (Poster): Education & Training Group 21 Systematics & Evolution Group 21 Environmental Microbiology Group / Food & Beverages Group Joint Meeting Symposium: DNA-based detection methods 25 Offered papers (Poster): Environmental Microbiology Group 28 Food & Beverages Group 32 SGM Eukaryotic Microbiology Group / British Mycological Society / British Society for Medical Mycology Symposium: Post genomics applied to processes: advances in eukaryotic microbiology 37 Offered papers (Poster) 41 Fermentation & Bioprocessing Group Symposium: From molecular genetics, design and application to manufacturing 45 and regulatory issues of DNA at large scale Offered papers (Poster) 46 Microbial Infection Group: Symposium: Bacterial gene expression in vivo 47 Offered papers (Poster) 50 Physiology, Biochemistry & Molecular Genetics Group Symposium: DNA 1953-2003: from structure to function 61 Offered papers (Poster) 62 YOUNG MICROBIOLOGIST OF THE YEAR 71 INDEX OF AUTHORS 75 LATE ENTRIES 79 Society for General Microbiology – 153rd Meeting – UMIST, Manchester – 8-11 September 2003 - 1 - Society for General Microbiology – 153rd Meeting – UMIST, Manchester – 8-11 September 2003 - 2 - MAIN
    [Show full text]